AR076850A1 - Derivados sustituidos de indazol y aza-indazol como moduladores de la gamma secretasa. - Google Patents

Derivados sustituidos de indazol y aza-indazol como moduladores de la gamma secretasa.

Info

Publication number
AR076850A1
AR076850A1 ARP100101549A ARP100101549A AR076850A1 AR 076850 A1 AR076850 A1 AR 076850A1 AR P100101549 A ARP100101549 A AR P100101549A AR P100101549 A ARP100101549 A AR P100101549A AR 076850 A1 AR076850 A1 AR 076850A1
Authority
AR
Argentina
Prior art keywords
halo
hydrogen
alkyl
alkyloxy
substituents
Prior art date
Application number
ARP100101549A
Other languages
English (en)
Original Assignee
Ortho Mcneil Janssen Pharm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Janssen Pharm filed Critical Ortho Mcneil Janssen Pharm
Publication of AR076850A1 publication Critical patent/AR076850A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Estos compuestos son utiles como moduladores de la gamma secretasa. Se proveen además composiciones farmacéuticas que comprenden dichos compuestos como ingrediente activo como así también con el uso de dichos compuestos como medicamento para el tratamiento de la enfermedad de Alzheimer y otras formas de demencia. Reivindicacion 1: Un compuesto de formula (1) y formas estereoisoméricas del mismo, en donde R1 es alquilo C1-6 opcionalmente sustituido con uno o más sustituyentes cada uno independientemente seleccionado del grupo que consiste de halo, alquiloxi C1-4, cicloalquilo C3-7, tetrahidropiranilo, tetrahidrofuranilo y fenilo; cicloalquilo C3-7; tetrahidropiranilo; tetrahidrofuranilo; 1,3-benzodioxolilo; o fenilo; en donde cada fenilo independientemente es opcionalmente sustituido con uno o más sustituyentes cada uno independientemente seleccionado del grupo que consiste de halo, ciano, alquilo C1-4 opcionalmente sustituido con uno o más sustituyentes halo, y alquiloxi C1-4 opcionalmente sustituido con uno o más sustituyentes halo; R2 es hidrogeno; ciano; o alquilo C1-4 opcionalmente sustituido con uno o más sustituyentes cada uno independientemente seleccionado del grupo que consiste de alquiloxi C1-4, halo y NR3R4; X1 es CH o N; X2 es CR5 o N; R5 es hidrogeno; halo; ciano; alquiloxi C1-4 o alquilo C1-4 opcionalmente sustituido con uno o más sustituyentes cada uno independientemente seleccionado del grupo que consiste de halo, alquiloxi C1-4 y NR3R4; X3 es CR6 o N; R6 es hidrogeno; halo; ciano; alquiloxi C1-4 o alquilo C1-4 opcionalmente sustituido con uno o más sustituyentes cada uno independientemente seleccionado del grupo que consiste de halo, alquiloxi C1-4 y NR3R4, en donde cada R3 es independientemente hidrogeno; alquilo C1-4; o acilo C1-4; en donde cada R4 es independientemente hidrogeno; alquilo C1-4, o acilo C1-4; con la condicion de que no más de dos de X1, X2 y X3 sean N; A1 es CR7 o N; en donde R7 es hidrogeno, halo o alquiloxi C1-4; A2, A3 y A4 cada uno independientemente son CH o N; con la condicion de que no más de dos de A1, A2, A3 y A4 sean N; Het1 es un heterociclo aromático de miembros, de formula (a-1), (a-2), (a-3) o (a-4), R8 es hidrogeno o alquilo C1-4; R9 es hidrogeno o alquilo C1-4; R10 es hidrogeno o alquilo C1-4; R11 es hidrogeno o alquilo C1-4; R12 es alquilo C1-4; G1 es O o S; G2 es CH o N; y sales de adicion, y los solvatos farmacéuticamente aceptables de los mismos.
ARP100101549A 2009-05-07 2010-05-06 Derivados sustituidos de indazol y aza-indazol como moduladores de la gamma secretasa. AR076850A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09159615 2009-05-07

Publications (1)

Publication Number Publication Date
AR076850A1 true AR076850A1 (es) 2011-07-13

Family

ID=40786448

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100101549A AR076850A1 (es) 2009-05-07 2010-05-06 Derivados sustituidos de indazol y aza-indazol como moduladores de la gamma secretasa.

Country Status (20)

Country Link
US (1) US8835482B2 (es)
EP (1) EP2427453B1 (es)
JP (1) JP5559309B2 (es)
KR (1) KR20120024555A (es)
CN (1) CN102439005B (es)
AR (1) AR076850A1 (es)
AU (1) AU2010262036B2 (es)
BR (1) BRPI1011190A8 (es)
CA (1) CA2755467A1 (es)
EA (1) EA019702B1 (es)
ES (1) ES2431619T3 (es)
IL (1) IL216113A (es)
MX (1) MX2011011753A (es)
MY (1) MY152998A (es)
NZ (1) NZ596843A (es)
SG (1) SG175317A1 (es)
TW (1) TWI461419B (es)
UA (1) UA105377C2 (es)
WO (1) WO2010145883A1 (es)
ZA (1) ZA201108117B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8854101A1 (es) 2008-12-18 2010-07-27 Ortho Mcneil Janssen Pharm Derivados de imidazol bicíclicos sustituidos como moduladores de gamma secretasa
BRPI1008473A2 (pt) 2009-02-06 2019-04-02 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. compostos heterocíclicos bicíclicos substituídos como moduladores de gama secretase
TWI461425B (zh) 2009-02-19 2014-11-21 Janssen Pharmaceuticals Inc 作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類
BRPI1011190A8 (pt) 2009-05-07 2016-11-16 Janssen Pharmaceuticals Inc Derivados de indazol e aza-indazol substituídos como moduladores de gama secretase
KR20120050450A (ko) 2009-07-15 2012-05-18 얀센 파마슈티칼즈, 인코포레이티드 감마 세크레타제 조절제로서의 치환된 트리아졸 및 이미다졸 유도체
JP5824464B2 (ja) 2010-01-15 2015-11-25 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド γセクレターゼ調節物質としての新規置換トリアゾール誘導体
WO2012126984A1 (en) 2011-03-24 2012-09-27 Janssen Pharmaceuticals, Inc. Novel substituted triazolyl piperazine and triazolyl piperidine derivatives as gamma secretase modulators
ES2555167T3 (es) 2011-07-15 2015-12-29 Janssen Pharmaceuticals, Inc. Nuevos derivados de indol sustituidos como moduladores de gamma secretasa
MX355164B (es) 2012-05-16 2018-04-06 Janssen Pharmaceuticals Inc Derivados de 3,4-dihidro-2h-pirido[1,2-a]pirazin-1,6-diona sustituidos utiles para el tratamiento de la enfermedad de alzheimer (inter alia).
EP2953949B1 (en) 2012-12-20 2016-09-28 Janssen Pharmaceutica NV Novel tricyclic 3,4-dihydro-2h-pyrido[1,2-a]pyrazine-1,6-dione derivatives as gamma secretase modulators
WO2014111457A1 (en) 2013-01-17 2014-07-24 Janssen Pharmaceutica Nv Novel substituted pyrido-piperazinone derivatives as gamma secretase modulators
EP2958918B1 (en) * 2013-02-21 2016-12-07 Boehringer Ingelheim International GmbH Dihydropteridinones ii
US10562897B2 (en) 2014-01-16 2020-02-18 Janssen Pharmaceutica Nv Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators
CN103880683B (zh) * 2014-02-26 2018-06-22 南通大学 一种3-溴-2-硝基苯甲醛的化学合成方法
EP3347363B1 (en) * 2015-09-09 2020-01-01 H. Hoffnabb-La Roche Ag N-(3-azabicyclo[3.2.1]octan-8-yl)-8-(4-phenyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[l,5-a]pyridin-2-amine derivatives as gamma-secretase modulators for treating alzheimer's disease
CN105585547A (zh) * 2016-03-09 2016-05-18 中国科学院广州生物医药与健康研究院 一种4-五氟化硫苯酚类化合物及制备方法以及五氟化硫取代苯并吡喃类化合物的制备方法
CN114195702A (zh) * 2020-09-18 2022-03-18 瑞博(杭州)医药科技有限公司 一种用于合成抗肿瘤药物尼拉帕利的中间体及其制备方法

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5767144A (en) 1994-08-19 1998-06-16 Abbott Laboratories Endothelin antagonists
DE60012742T2 (de) * 1999-06-10 2005-01-13 Warner-Lambert Co. Llc Inhibition von amyloid protein aggregation und bilderzeugung von amyloidniederschlägen mit isoindolderivate
EP1284729A4 (en) 2000-04-13 2007-12-19 Mayo Foundation REDUCTION AGENTS OF A (BETA) 42
US20030176454A1 (en) 2000-05-15 2003-09-18 Akira Yamada N-coating heterocyclic compounds
DE10238002A1 (de) 2002-08-20 2004-03-04 Merck Patent Gmbh Benzimidazolderivate
BRPI0407913A (pt) 2003-02-27 2006-03-01 Hoffmann La Roche antagonistas receptores de ccr-3
BRPI0410348A (pt) * 2003-05-14 2006-05-30 Torreypines Therapeutics Inc compostos e usos dos mesmos na modulação de amilóide-beta
AU2004265101B2 (en) 2003-08-14 2009-06-11 F. Hoffmann-La Roche Ag Gabanergic modulators
WO2005085245A1 (en) 2004-03-08 2005-09-15 Prosidion Limited Pyrrolopyridine-2-carboxylic acid hydrazides
TWI335816B (en) 2004-05-26 2011-01-11 Eisai R&D Man Co Ltd Cinnamide compound
JPWO2006046575A1 (ja) 2004-10-26 2008-05-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 シンナミド化合物の非晶質体
US7572807B2 (en) 2005-06-09 2009-08-11 Bristol-Myers Squibb Company Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
AU2006293635A1 (en) 2005-09-22 2007-03-29 Sanofi-Aventis Amino-alkyl-amide derivatives as CCR3 receptor liquids
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
WO2007043786A1 (en) 2005-10-10 2007-04-19 Seiyang Yang Dynamic-based verification apparatus for verification from electronic system level to gate level, and verification method using the same
JP4987873B2 (ja) 2005-10-11 2012-07-25 ケムチュア コーポレイション 二芳香族アミン
JP2009539762A (ja) 2006-03-13 2009-11-19 ファイザー・プロダクツ・インク Ｈ３受容体のテトラリン拮抗薬
GB0606774D0 (en) 2006-04-03 2006-05-10 Novartis Ag Organic compounds
US7893058B2 (en) 2006-05-15 2011-02-22 Janssen Pharmaceutica Nv Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases
EP2099798A1 (en) 2006-12-01 2009-09-16 Galapagos N.V. Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases
MX2009006863A (es) 2006-12-20 2009-08-28 Schering Corp Inhibidores novedosos de c-jun-n-terminal cinasas.
US8183276B2 (en) 2007-02-08 2012-05-22 Christian Fischer Therapeutic agents
EP2120573A4 (en) 2007-02-12 2011-05-25 Merck Sharp & Dohme DERIVATIVES OF PIPERIDINE
EP2121633A2 (en) 2007-02-12 2009-11-25 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
WO2008137139A1 (en) 2007-05-07 2008-11-13 Schering Corporation Gamma secretase modulators
CA2686754C (en) * 2007-05-11 2014-10-28 F. Hoffmann-La Roche Ag Hetarylanilines as modulators for amyloid beta
WO2008156580A1 (en) 2007-06-13 2008-12-24 Merck & Co., Inc. Triazole derivatives for treating alzheimer's disease and related conditions
CN101772493A (zh) 2007-06-29 2010-07-07 先灵公司 γ分泌酶调节剂
US7935815B2 (en) 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
CN101848897A (zh) 2007-09-06 2010-09-29 先灵公司 γ分泌酶调节剂
CN101903775A (zh) 2007-10-19 2010-12-01 Erac股份有限公司 抗edta的s100a12c复合物(erac)
WO2009073777A1 (en) 2007-12-06 2009-06-11 Schering Corporation Gamma secretase modulators
EP2227471A1 (en) 2007-12-11 2010-09-15 Schering Corporation Gamma secretase modulators
JP5328816B2 (ja) 2008-02-22 2013-10-30 エフ．ホフマン−ラ ロシュ アーゲー アミロイドβの調節薬
US20100137320A1 (en) 2008-02-29 2010-06-03 Schering Corporation Gamma secretase modulators
WO2010010188A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases.
WO2010054067A1 (en) 2008-11-06 2010-05-14 Schering Corporation Gamma secretase modulators
AU2009312856A1 (en) 2008-11-10 2010-05-14 F. Hoffmann-La Roche Ag Heterocyclic gamma secretase modulators
JP2012510515A (ja) 2008-12-03 2012-05-10 ブイアイエイ・ファーマシューティカルズ・インコーポレーテッド ジアシルグリセロールアシルトランスフェラーゼの阻害剤
PA8854101A1 (es) 2008-12-18 2010-07-27 Ortho Mcneil Janssen Pharm Derivados de imidazol bicíclicos sustituidos como moduladores de gamma secretasa
TW201030002A (en) 2009-01-16 2010-08-16 Bristol Myers Squibb Co Bicyclic compounds for the reduction of beta-amyloid production
BRPI1008473A2 (pt) 2009-02-06 2019-04-02 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. compostos heterocíclicos bicíclicos substituídos como moduladores de gama secretase
TWI461425B (zh) 2009-02-19 2014-11-21 Janssen Pharmaceuticals Inc 作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類
JP2012051806A (ja) 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd イミダゾリルピラジン誘導体
NZ594776A (en) 2009-02-26 2013-05-31 Eisai R&D Man Co Ltd Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors
JP2012051807A (ja) 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd アリールイミダゾール化合物
US20120053165A1 (en) 2009-03-03 2012-03-01 Pfizer Inc. Novel Phenyl Imidazoles and Phenyl Triazoles As Gamma-Secretase Modulators
EP2410529A1 (en) 2009-03-16 2012-01-25 Panasonic Corporation Application running device
CA2758958A1 (en) 2009-04-27 2010-11-04 High Point Pharmaceuticals, Llc Substituted imidazo[1,2-a]pyridine derivatives, pharmaceutical compositions, and methods of use as .beta.-secretase inhibitors
BRPI1011190A8 (pt) 2009-05-07 2016-11-16 Janssen Pharmaceuticals Inc Derivados de indazol e aza-indazol substituídos como moduladores de gama secretase
JP2010274429A (ja) 2009-05-26 2010-12-09 Ihi Corp アライメントステージ
KR20120050450A (ko) 2009-07-15 2012-05-18 얀센 파마슈티칼즈, 인코포레이티드 감마 세크레타제 조절제로서의 치환된 트리아졸 및 이미다졸 유도체
JP5824464B2 (ja) 2010-01-15 2015-11-25 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド γセクレターゼ調節物質としての新規置換トリアゾール誘導体
WO2012126984A1 (en) 2011-03-24 2012-09-27 Janssen Pharmaceuticals, Inc. Novel substituted triazolyl piperazine and triazolyl piperidine derivatives as gamma secretase modulators
EP2691393B1 (en) 2011-03-31 2016-09-14 Pfizer Inc Novel bicyclic pyridinones
ES2555167T3 (es) 2011-07-15 2015-12-29 Janssen Pharmaceuticals, Inc. Nuevos derivados de indol sustituidos como moduladores de gamma secretasa

Also Published As

Publication number Publication date
KR20120024555A (ko) 2012-03-14
ZA201108117B (en) 2015-06-24
EA201171363A1 (ru) 2012-04-30
AU2010262036A1 (en) 2011-09-22
UA105377C2 (uk) 2014-05-12
CA2755467A1 (en) 2010-12-23
WO2010145883A1 (en) 2010-12-23
JP2012526078A (ja) 2012-10-25
MY152998A (en) 2014-12-31
EP2427453A1 (en) 2012-03-14
JP5559309B2 (ja) 2014-07-23
TW201105658A (en) 2011-02-16
EA019702B1 (ru) 2014-05-30
TWI461419B (zh) 2014-11-21
IL216113A (en) 2015-02-26
BRPI1011190A2 (pt) 2016-03-15
BRPI1011190A8 (pt) 2016-11-16
CN102439005A (zh) 2012-05-02
MX2011011753A (es) 2011-11-29
NZ596843A (en) 2012-12-21
AU2010262036B2 (en) 2014-10-30
US20120095036A1 (en) 2012-04-19
ES2431619T3 (es) 2013-11-27
US8835482B2 (en) 2014-09-16
SG175317A1 (en) 2011-11-28
EP2427453B1 (en) 2013-07-17
IL216113A0 (en) 2012-01-31
CN102439005B (zh) 2015-07-22

Similar Documents

Publication Publication Date Title
AR076850A1 (es) Derivados sustituidos de indazol y aza-indazol como moduladores de la gamma secretasa.
AR084849A1 (es) Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos
AR075520A1 (es) Nuevos derivados sustituidos de benzoxazol bencimidazol oxazolopiridina e imidazopiridina como moduladores de gamma secretasa
CO7160015A2 (es) Benzamidas n-sustituidas y su uso en el tratamiento del dolor
AR081426A1 (es) Derivados de pirazol inhibidores del receptor sigma
AR085960A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
AR073598A1 (es) Pirrolidinas 2-carboxamidas sustituidas, composiciones farmaceuticas que las contienen y uso de las mismas como agentes anticancer.
CO6210729A2 (es) Derivados de sulfonil-fenil-2h-[1,2,4]oxadiazol-5-ona procedimientos para su preparacion y su uso como agente farmaceutico
AR085004A1 (es) Inhibidores selectivos de glicosidasas y usos de los mismos
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
ECSP066829A (es) 5,6 dialquil-7 -amino-triazolopirimidinas, procedimientos para su preparacion y el uso de las mismas para combatir hongos nocivos
UY32462A (es) Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644
CU20110145A7 (es) Derivados de sulfonamida
UY31906A (es) Derivados de n-cicloalquil-3-fenilnicotinamida que inhiben pgds, sus composiciones, su uso para el tratamiento por ejemplo de afecciones alérgicas y respiratorias.
AR044005A1 (es) Compuestos biciclicos, procedimiento para su preparacion, su uso para preparar un medicamento y composiciones farmaceuticas que los comprenden
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
AR085549A1 (es) DERIVADOS TRIAZOLIL PIPERAZINA Y TRIAZOLIL PIPERIDINA SUSTITUIDOS COMO MODULADORES DE g SECRETASA
AR083798A1 (es) Inhibidores selectivos de glucosidasas y sus usos
CU23761B7 (es) Nuevos derivados de diosmetina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
UY30938A1 (es) Derivados de nicotinamida, sales y solvatos farmacéuticamente aceptables, composiciones y aplicaciones.
MY165634A (en) Pyrazole compounds having therapeutic effect on multiple myeloma
AR066242A1 (es) Tia(di)azoles como antagonistas del recpetor de dopamina 2 de disociacion rapida
AR072880A1 (es) Derivados nitrogenados de la pancratistatina
UY32744A (es) Derivados de 2-carboxamida-7-piperazinil-benzofurano 774
EA201390374A1 (ru) Гетероциклические соединения для лечения или профилактики расстройств, вызываемых ослабленной нейротрансмиссией серотонина, норэпинефрина или допамина

Legal Events

Date Code Title Description
FA Abandonment or withdrawal